Protagonist Therapeutics (PTGX) Cash from Financing Activities (2015 - 2026)

Protagonist Therapeutics has disclosed Cash from Financing Activities across 12 years of filings, most recently posting $23.4 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $23.4 million, up 104.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $34.8 million (up 15.61% YoY), and the FY2025 annual result was $22.9 million, down 11.56% from the prior year.
• Cash from Financing Activities came in at $23.4 million for Q1 2026 at Protagonist Therapeutics, up from $2.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $108.2 million in Q2 2023 to a low of $527000.0 in Q4 2023.
• The 5-year median for Cash from Financing Activities is $5.7 million (2025), against an average of $15.4 million.
• Across the five-year window, Cash from Financing Activities tumbled 99.46% in 2022 and surged 15807.65% in 2023, its largest moves.
• Protagonist Therapeutics' Cash from Financing Activities stood at $553000.0 in 2022, then dropped by 4.7% to $527000.0 in 2023, then jumped by 664.9% to $4.0 million in 2024, then fell by 29.62% to $2.8 million in 2025, then soared by 723.9% to $23.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $23.4 million (Q1 2026), $2.8 million (Q4 2025), and $5.7 million (Q3 2025), per Business Quant data.